FDA evaluating pancreatitis risk with incretin drugs

Written by Jyothis George on 17 March 2013. Modified on 17 March 2013. Hits: 4758

AddThis Social Bookmark Button

The FDA is evaluating unpublished new findings suggesting an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with  incretin mimetics.

The FDA website says "FDA has not reached any new conclusions about safety risks with incretin mimetic drugs. This early communication is intended only to inform the public and health care professionals that the Agency intends to obtain and evaluate this new information. FDA will communicate its final conclusions and recommendations when its review is complete or when the Agency has additional information to report."

Read more here

Our latest tweets